{
    "nctId": "NCT03348098",
    "briefTitle": "Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer",
    "officialTitle": "Tianjin Medical University Cancer Institute and Hospital",
    "overallStatus": "UNKNOWN",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "ORR",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. patients between18 and 75 Years old;\n2. patients with locally advanced breast cancer (TNM periodization:T is equal to or greater than 2,N is equal to 1,M is equal to 0)\n3. clear for immunohistochemical is that: estrogen receptor-negative (ER-), progesterone receptor-negative (PR-), the human epidermal growth factor receptor 2 is Negative ( IHC Her-2 0/+ , If ER- \u3001 PR- But Her-2 ++ , You need to do FISH/CISH Testing confirmed that Her-2 Amplification is negative);\n4. The ECOG score is between 0 to 2 points;\n5. The expected lifetime is \u22653 months;\n6. Major organ function is normal, that meet the following criteria:\n\n   1. Blood test standards subject to:\n\n      HB\u226590 g/L ;\n\n      ANC\u22651.5\u00d7109 /L ;\n\n      PLT\u2265100\u00d7109 /L ;\n   2. Biochemical examination must meet the following criteria:\n\n   TBIL\u22641.5xULN ( upper limit of normal value ) ;\n\n   ALT AST\u22642.5\u00d7ULN ;\n\n   Serum Cr\u22641.5\u00d7ULN And endogenous creatinine clearance rate \u226550 mL/min (Cockcroft-Gault formula ) ;\n7. the women of childbearing age must do the pregnancy test ( serum or urine ) within 7 days when they are included in the trial, And the result was negative, and during the trial and at the time of giving experimental drugs after 8 weeks using the appropriate methods of contraception;\n8. no difficulty in swallowing, swallowing oral medications;\n9. the participants volunteered to join this study should sign the informed consent forms, have better compliance, work in with the follow-up\n\nExclusion Criteria:\n\n1. patients with pregnancy or lactation;\n2. inflammatory breast cancer patients;\n3. patients with several factors affecting medication (for example, inability to swallow, such as nausea, vomiting, chronic diarrhea, and bowel obstruction);\n4. injury or pathologic fracture;\n5. people with high blood pressure and antihypertensive drug treatment could not be reduced to within the normal range (systolic \\>140 mmHg, diastolic pressure \\>90 mmHg) ;\n6. with \u2171 grade myocardial ischemia, poor control of arrhythmias or myocardial infarction (including QTc interval men \u2265450 Ms, female \u2265470 Ms);\n7. according to NYHA standard \u2172\\~\u2173 -class heart insufficiency or heart ultrasound: LVEF(left ventricular ejection fraction) \\<50%;\n8. the past 6 months have gastrointestinal bleeding within history or definite gastrointestinal bleeding, such as: risk of bleeding oesophageal varicose ulcer lesions, fecal occult blood, local activities \u2265 (++) Into groups; such as the fecal occult blood (+), requires endoscopy;\n9. prior to participating in the study of 28 days abdominal fistula, perforation of the gastrointestinal tract and abdominal abscesses;\n10. positive patients of urinary protein (urine protein 2+ or above, or 24 -hour urine protein \\> 1.0g);\n11. distant metastasis of patients with symptoms or are not controlled;\n12. expected lifetime \\< 3 months;\n13. into the group before 28 days to accept other anticancer treatment;\n14. other information: dysfunction of blood coagulation (INR\\>1.5 or prothrombin time ( PT )\\> ULN+4 Seconds); Anticoagulant therapy are receiving antithrombotic or infection who needed intravenous antibiotics; previously receiving bevacizumab treatment or other anti- VEGF TKI Drug treatment, with a second tumor (except basal cell carcinoma and cervical carcinoma in situ);\n15. a history of immunodeficiency, including HIV testing positive, or suffer from other acquired, congenital immune deficiency disease or have a history of organ transplantation;",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}